Cencora (NYSE:COR) Given New $388.00 Price Target at Leerink Partners

Posted by Geri Gentry on Oct 7th, 2026

Cencora (NYSE:COR – Get Free Report) had its target price lifted by equities research analysts at Leerink Partners from $380.00 to $388.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners’ price target indicates a potential upside of 21.42% from the stock’s current price.

Other analysts have also recently issued reports about the company. Evercore reaffirmed an “outperform” rating and set a $350.00 price objective on shares of Cencora in a research report on Thursday, August 6th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Morgan Stanley upped their price target on Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Barclays cut their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Finally, Citigroup reaffirmed a “buy” rating on shares of Cencora in a report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $372.07.

View Our Latest Research Report on Cencora

Cencora Stock Performance

Cencora stock traded up $3.18 during midday trading on Wednesday, hitting $319.55. 298,657 shares of the company’s stock were exchanged, compared to its average volume of 1,482,011. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The stock has a market cap of $60.98 billion, a price-to-earnings ratio of 23.75, a price-to-earnings-growth ratio of 1.62 and a beta of 0.58. Cencora has a 12-month low of $244.82 and a 12-month high of $377.54. The firm’s 50 day simple moving average is $318.12 and its 200 day simple moving average is $302.86.

Cencora (NYSE:COR – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business had revenue of $84.75 billion during the quarter, compared to analysts’ expectations of $84.31 billion. During the same period in the prior year, the company earned $4.00 earnings per share. The business’s revenue was up 5.1% compared to the same quarter last year. Equities research analysts predict that Cencora will post 17.87 EPS for the current year.

Insider Activity at Cencora

In related news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cencora

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Park National Corp OH boosted its stake in shares of Cencora by 115.2% during the 3rd quarter. Park National Corp OH now owns 73,966 shares of the company’s stock worth $22,208,000 after acquiring an additional 39,594 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in Cencora by 62.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 1,419 shares of the company’s stock valued at $426,000 after purchasing an additional 545 shares in the last quarter. Polaris Financial Partners acquired a new position in Cencora during the third quarter worth $96,000. Versant Capital Management Inc boosted its position in Cencora by 50.6% during the third quarter. Versant Capital Management Inc now owns 946 shares of the company’s stock worth $284,000 after purchasing an additional 318 shares in the last quarter. Finally, Burkett Financial Services LLC purchased a new stake in Cencora during the third quarter worth $67,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Company Profile

(Get Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.